Panretin (Alitretinoin Topical) - Summary

PANRETIN SUMMARY

Panretin®
(alitretinoin)
gel 0.1%
(For topical use only)

Panretin® gel 0.1% contains alitretinoin and is intended for topical application only.

Panretin® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Panretin® gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin® gel with systemic anti-KS treatment.

See all Panretin indications & dosage >>

PANRETIN NEWS HIGHLIGHTS

Published Studies Related to Panretin (Alitretinoin Topical)

Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. [2008.04]

Alitretinoin: a comprehensive review. [2008.03]

[Kaposi's sarcoma treated with topical alitretinoin] [2007.01]

Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. [2005.07]

more >>

Clinical Trials Related to Panretin (Alitretinoin Topical)

A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients [Completed]

A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma [Completed]

A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma [Completed]

Alitretinoin in the Treatment of Chronic Hand Eczema [Recruiting]

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis [Completed]

more >>